Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Cash & Equivalents (2018 - 2025)

Summit Therapeutics (SMMT) has disclosed Cash & Equivalents for 7 consecutive years, with $238.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents rose 154.39% year-over-year to $238.6 million, compared with a TTM value of $238.6 million through Sep 2025, up 154.39%, and an annual FY2024 reading of $104.9 million, up 46.81% over the prior year.
  • Cash & Equivalents was $238.6 million for Q3 2025 at Summit Therapeutics, down from $297.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $348.6 million in Q4 2022 and bottomed at $23.8 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $129.8 million, with a median of $98.0 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents crashed 79.51% in 2023, then soared 947.59% in 2025.
  • Year by year, Cash & Equivalents stood at $71.8 million in 2021, then surged by 385.59% to $348.6 million in 2022, then plummeted by 79.51% to $71.4 million in 2023, then surged by 46.81% to $104.9 million in 2024, then soared by 127.49% to $238.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for SMMT at $238.6 million in Q3 2025, $297.9 million in Q2 2025, and $211.5 million in Q1 2025.